NASDAQ
34.56USD
-0.08 (-0.23%)
We have scored 11 news catalysts on Definium Therapeutics, Inc. (DFTX) over the past 12 months. The biggest single-day move next to one of them came Jun 22, 2026, when DFTX closed +49.8%: “Definium Therapeutics shares surge on positive late-stage trial results for LSD-based depression therapy”. Coverage across the window leans positive (average ticker sentiment +0.54). Most of the impact sits in price momentum and forward growth expectations.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
4.6B
P/E
—
EPS
—
Beta
2.21
52W range
12.882-49.2
Day range
33.95–35.23
Open
35.23
Prev close
34.64
Volume
427.5K
Avg volume
2.1M
Dividend
0.00
IPO
2016-11-15
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Definium Therapeutics, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for DFTX: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.
